Overall, there are significant challenges for patients with HRAS-mutant HNSCC, where there are high rates of recurrence (50–67% relapse in less than 6 months) and short disease-free survival (4 months) [98]. Here, HRAS is linked to head and neck squamous cell carcinoma.